HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Over the last 12 months, insiders at HOOKIPA Pharma Inc. have bought $38,445 and sold $0 worth of HOOKIPA Pharma Inc. stock.
On average, over the past 5 years, insiders at HOOKIPA Pharma Inc. have bought $38,445 and sold $3.92M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Kandera Reinhard (Chief Financial Officer) — $21,347. Aldag Jorn (Chief Executive Officer) — $17,098.
The last purchase of 7,000 shares for transaction amount of $5,075 was made by Kandera Reinhard (Chief Financial Officer) on 2023‑08‑21.
2023-08-21 | Kandera Reinhard | Chief Financial Officer | 7,000 0.0091% | $0.72 | $5,075 | -5.21% | ||
2023-08-16 | Kandera Reinhard | Chief Financial Officer | 8,000 0.0103% | $0.71 | $5,712 | -3.36% | ||
2023-07-11 | Aldag Jorn | Chief Executive Officer | 5,000 0.007% | $0.83 | $4,142 | -13.60% | ||
2023-07-07 | Aldag Jorn | Chief Executive Officer | 5,000 0.0068% | $0.81 | $4,050 | -13.77% | ||
2023-07-05 | Aldag Jorn | Chief Executive Officer | 5,000 0.0071% | $0.89 | $4,450 | -18.22% | ||
2023-07-03 | Aldag Jorn | Chief Executive Officer | 5,000 0.0072% | $0.89 | $4,456 | -16.55% | ||
2023-06-30 | Kandera Reinhard | Chief Financial Officer | 12,000 0.0166% | $0.88 | $10,560 | -19.05% | ||
2021-12-21 | Sale | Matushansky Igor | Chief Medical Officer | 14,949 0.0457% | $2.49 | $37,223 | -37.90% | |
2021-04-21 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 328,620 0.9448% | $11.60 | $3.81M | -58.05% | |
2021-03-29 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 36,829 0.1234% | $13.67 | $503,570 | -54.96% | |
2021-03-26 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 35,171 0.1167% | $13.69 | $481,642 | -54.91% | |
2021-03-25 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 28,546 0.093% | $13.12 | $374,569 | -53.55% | |
2021-03-24 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 52,690 0.1841% | $13.70 | $721,616 | -52.05% | |
2021-03-23 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 40,000 0.1374% | $13.91 | $556,476 | -53.53% | |
2021-03-22 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 40,534 0.1369% | $14.54 | $589,263 | -55.71% | |
2021-03-19 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 166,230 0.5544% | $14.60 | $2.43M | -56.39% | |
2020-12-17 | Sale | Matushansky Igor | Chief Medical Officer | 27,979 0.1031% | $11.74 | $328,343 | -20.23% | |
2020-12-16 | Sale | Matushansky Igor | Chief Medical Officer | 380 0.0014% | $11.70 | $4,446 | -18.84% | |
2020-10-02 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 300 0.0011% | $10.00 | $3,000 | +13.55% | |
2020-09-15 | Sale | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 41,597 0.1949% | $12.61 | $524,477 | +5.48% |
Aldag Jorn | Chief Executive Officer | 71952 0.0882% | $0.64 | 4 | 0 | |
Kandera Reinhard | Chief Financial Officer | 43092 0.0528% | $0.64 | 3 | 0 | |
SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3177574 3.8964% | $0.64 | 1 | 12 | <0.0001% |
Forbion Capital Fund II Cooperatief U.A. | 10 percent owner | 2494173 3.0584% | $0.64 | 1 | 0 | <0.0001% |
BAKER BROS. ADVISORS LP | 820729 1.0064% | $0.64 | 1 | 0 | <0.0001% | |
Matushansky Igor | Chief Medical Officer | 80178 0.0983% | $0.64 | 0 | 6 | |
Lilja Anders | Sr. VP, Technical Development | 0 0% | $0.64 | 0 | 1 | |
Orlinger Klaus | Sr. VP, Research | 0 0% | $0.64 | 0 | 3 |
Baker Bros Advisors LP | $5.79M | 8.21 | 8.13M | 0% | +$0 | 0.07 | |
Artal Group S A | $4.03M | 5.73 | 5.67M | 0% | +$0 | 0.02 | |
Tupelo Capital Management LLC | $3.93M | 5.58 | 5.52M | 0% | +$0 | 2.57 | |
Ecor1 Capital Llc | $3.27M | 4.64 | 4.6M | 0% | +$0 | 0.08 | |
Fidelity Investments | $2.39M | 3.39 | 3.36M | 0% | +$0 | <0.0001 | |
The Vanguard Group | $1.51M | 2.14 | 2.12M | +0.17% | +$2,573.17 | <0.0001 | |
Morgan Stanley | $882,931.00 | 1.25 | 1.24M | +4.73% | +$39,871.99 | <0.0001 | |
Redmile Group | $757,404.00 | 1.08 | 1.06M | 0% | +$0 | 0.03 | |
Acadian Asset Management | $627,000.00 | 0.89 | 882,262 | +85.84% | +$289,622.09 | <0.01 | |
Geode Capital Management | $473,332.00 | 0.67 | 664,610 | +13.49% | +$56,265.55 | <0.0001 | |
Ikarian Capital LLC | $377,913.00 | 0.54 | 530,776 | 0% | +$0 | 0.11 | |
BlackRock | $205,976.00 | 0.29 | 289,293 | -1.69% | -$3,545.04 | <0.0001 | |
Renaissance Technologies | $156,000.00 | 0.22 | 218,446 | +15.8% | +$21,281.23 | <0.0001 | |
Royal Bank of Canada | $150,000.00 | 0.21 | 210,297 | -4.55% | -$7,157.02 | <0.0001 | |
Susquehanna International Group | $127,658.00 | 0.18 | 179,295 | New | +$127,658.00 | <0.0001 | |
State Street | $114,055.00 | 0.16 | 160,190 | 0% | +$0 | <0.0001 | |
Northern Trust | $111,663.00 | 0.16 | 156,830 | +41.3% | +$32,635.96 | <0.0001 | |
Boothbay Fund Management LLC | $83,799.00 | 0.12 | 117,695 | 0% | +$0 | <0.01 | |
Two Sigma | $67,468.00 | 0.1 | 94,759 | +491.65% | +$56,064.68 | <0.0001 | |
Bridgeway Capital Management | $62,300.00 | 0.09 | 87,500 | 0% | +$0 | <0.01 | |
Prudential Financial | $45,995.00 | 0.07 | 64,600 | New | +$45,995.00 | <0.0001 | |
Xtx Topco Ltd | $43,510.00 | 0.06 | 61,109 | -42.22% | -$31,792.51 | <0.01 | |
Tyler Stone Wealth Management | $33,571.00 | 0.05 | 47,150 | +21.21% | +$5,874.03 | 0.02 | |
Virtu Financial Llc | $31,000.00 | 0.04 | 43,021 | New | +$31,000.00 | <0.01 | |
Millennium Management LLC | $29,315.00 | 0.04 | 41,173 | -28.56% | -$11,720.87 | <0.0001 | |
Charles Schwab | $25,835.00 | 0.04 | 36,285 | 0% | +$0 | <0.0001 | |
Two Sigma Advisers LP | $25,347.00 | 0.04 | 35,600 | New | +$25,347.00 | <0.0001 | |
Hrt Financial Llc | $24,000.00 | 0.04 | 34,870 | New | +$24,000.00 | <0.0001 | |
Jane Street Capital | $18,514.00 | 0.03 | 26,002 | New | +$18,514.00 | <0.0001 | |
Beacon Pointe Advisors Llc | $16,661.00 | 0.02 | 23,400 | 0% | +$0 | <0.0001 | |
Apella Capital, LLC | $16,645.00 | 0.02 | 19,783 | 0% | +$0 | <0.01 | |
Group One Trading | $12,392.00 | 0.02 | 17,404 | 0% | +$0 | <0.0001 | |
International Assets Investment Management Llc | $10,129.00 | 0.01 | 14,000 | 0% | +$0 | <0.0001 | |
UBS | $8,835.00 | 0.01 | 12,408 | +112.43% | +$4,675.97 | <0.0001 | |
Tower Research Capital | $7,441.00 | 0.01 | 10,451 | +8.51% | +$583.83 | <0.0001 | |
Bank of America | $4,561.00 | 0.01 | 6,405 | -0.73% | -$33.47 | <0.0001 | |
Advisor Group Holdings Inc | $2,848.00 | <0.01 | 4,000 | 0% | +$0 | <0.0001 | |
Wells Fargo | $390.00 | <0.01 | 548 | +1.48% | +$5.69 | <0.0001 | |
JPMorgan Chase | $10.00 | <0.01 | 14 | 0% | +$0 | <0.0001 | |
Northwestern Mutual Wealth Management Co | $71.00 | <0.01 | 100 | New | +$71.00 | <0.0001 | |
Citigroup | $53.00 | <0.01 | 74 | 0% | +$0 | <0.0001 | |
Truvestments Capital Llc | $18.00 | <0.01 | 25 | New | +$18.00 | <0.0001 |